Which has stronger earnings and valuation, NUVB or CYTK?

Nuvation Bio has higher revenue and earnings than Cytokinetics. Nuvation Bio is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $169.90M 10.58 -$204.63M -$0.44 N/A Cytokinetics $67.67M 120.63 -$784.96M -$7.22 N/A

Is NUVB or CYTK more profitable?

Nuvation Bio has a net margin of -88.18% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Nuvation Bio's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% Cytokinetics -1,321.12% N/A -51.01%

Does the media favor NUVB or CYTK?

In the previous week, Cytokinetics had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 11 mentions for Cytokinetics and 9 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.38 beat Cytokinetics' score of 0.23 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ABVX or NUVB?

Nuvation Bio has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$6.06 N/A Nuvation Bio $169.90M 10.58 -$204.63M -$0.44 N/A

Is ABVX or NUVB more profitable?

Abivax has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -91.69% -71.96% Nuvation Bio -88.18% -46.59% -22.01%

Does the media prefer ABVX or NUVB?

In the previous week, Nuvation Bio had 4 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Nuvation Bio and 5 mentions for Abivax. Nuvation Bio's average media sentiment score of 0.38 beat Abivax's score of 0.22 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRAX or NUVB?

In the previous week, Nuvation Bio had 7 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 9 mentions for Nuvation Bio and 2 mentions for Praxis Precision Medicines. Nuvation Bio's average media sentiment score of 0.38 beat Praxis Precision Medicines' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NUVB or SYRE?

In the previous week, Spyre Therapeutics had 7 more articles in the media than Nuvation Bio. MarketBeat recorded 15 mentions for Spyre Therapeutics and 8 mentions for Nuvation Bio. Spyre Therapeutics' average media sentiment score of 0.43 beat Nuvation Bio's score of 0.33 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NUVB or IONS?

In the previous week, Nuvation Bio had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 8 mentions for Nuvation Bio and 5 mentions for Ionis Pharmaceuticals. Nuvation Bio's average media sentiment score of 0.33 beat Ionis Pharmaceuticals' score of 0.25 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nuvation Bio (NUVB) Competitors

$5.12 -0.44 (-7.90%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$5.20 +0.08 (+1.50%)

As of 10/2/2026 07:57 PM Eastern

Compare

NUVB vs. CYTK, ABVX, PRAX, SYRE, and IONS

Should you buy Nuvation Bio stock or one of its competitors? Nuvation Bio's main competitors and comparable companies include Cytokinetics (CYTK), Abivax (ABVX), Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), and Ionis Pharmaceuticals (IONS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvation Bio compare to Cytokinetics?

Nuvation Bio (NYSE:NUVB) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, Cytokinetics had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 11 mentions for Cytokinetics and 9 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.38 beat Cytokinetics' score of 0.23 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nuvation Bio has a net margin of -88.18% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Cytokinetics	-1,321.12%	N/A	-51.01%

Nuvation Bio currently has a consensus target price of $13.22, indicating a potential upside of 158.20%. Cytokinetics has a consensus target price of $106.00, indicating a potential upside of 61.59%. Given Nuvation Bio's higher possible upside, equities analysts clearly believe Nuvation Bio is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

Nuvation Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nuvation Bio has higher revenue and earnings than Cytokinetics. Nuvation Bio is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$169.90M	10.58	-$204.63M	-$0.44	N/A
Cytokinetics	$67.67M	120.63	-$784.96M	-$7.22	N/A

Summary

Nuvation Bio beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Abivax?

Abivax (NASDAQ:ABVX) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Abivax has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-91.69%	-71.96%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Abivax currently has a consensus price target of $156.69, suggesting a potential upside of 68.70%. Nuvation Bio has a consensus price target of $13.22, suggesting a potential upside of 158.20%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Nuvation Bio has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A
Nuvation Bio	$169.90M	10.58	-$204.63M	-$0.44	N/A

Abivax has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

In the previous week, Nuvation Bio had 4 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Nuvation Bio and 5 mentions for Abivax. Nuvation Bio's average media sentiment score of 0.38 beat Abivax's score of 0.22 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nuvation Bio beats Abivax on 12 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Praxis Precision Medicines presently has a consensus target price of $612.42, suggesting a potential upside of 107.24%. Nuvation Bio has a consensus target price of $13.22, suggesting a potential upside of 158.20%. Given Nuvation Bio's higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Nuvation Bio had 7 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 9 mentions for Nuvation Bio and 2 mentions for Praxis Precision Medicines. Nuvation Bio's average media sentiment score of 0.38 beat Praxis Precision Medicines' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Praxis Precision Medicines' return on equity of -34.15% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Nuvation Bio has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$12.93	N/A
Nuvation Bio	$169.90M	10.58	-$204.63M	-$0.44	N/A

Summary

Nuvation Bio beats Praxis Precision Medicines on 9 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Spyre Therapeutics?

Nuvation Bio (NYSE:NUVB) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Nuvation Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, indicating that its stock price is 210% more volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Spyre Therapeutics' return on equity of -30.74% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Spyre Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	28.59	-$204.63M	-$0.44	N/A
Spyre Therapeutics	$890K	9,208.01	-$155.20M	-$1.95	N/A

In the previous week, Spyre Therapeutics had 7 more articles in the media than Nuvation Bio. MarketBeat recorded 15 mentions for Spyre Therapeutics and 8 mentions for Nuvation Bio. Spyre Therapeutics' average media sentiment score of 0.43 beat Nuvation Bio's score of 0.33 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvation Bio currently has a consensus price target of $13.22, suggesting a potential upside of 158.20%. Spyre Therapeutics has a consensus price target of $109.71, suggesting a potential upside of 17.73%. Given Nuvation Bio's higher probable upside, equities research analysts clearly believe Nuvation Bio is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Spyre Therapeutics beats Nuvation Bio on 11 of the 17 factors compared between the two stocks.

How does Nuvation Bio compare to Ionis Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Nuvation Bio has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Ionis Pharmaceuticals has a net margin of -64.76% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

In the previous week, Nuvation Bio had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 8 mentions for Nuvation Bio and 5 mentions for Ionis Pharmaceuticals. Nuvation Bio's average media sentiment score of 0.33 beat Ionis Pharmaceuticals' score of 0.25 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvation Bio has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	28.59	-$204.63M	-$0.44	N/A
Ionis Pharmaceuticals	$944M	7.66	-$381.39M	-$3.46	N/A

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvation Bio presently has a consensus price target of $13.22, indicating a potential upside of 158.20%. Ionis Pharmaceuticals has a consensus price target of $89.20, indicating a potential upside of 104.87%. Given Nuvation Bio's higher possible upside, equities analysts plainly believe Nuvation Bio is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Nuvation Bio beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUVB vs. The Competition

Export

Metric	Nuvation Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.80B	$3.87B	$7.14B	$22.64B
Dividend Yield	N/A	3.64%	2.53%	3.73%
P/E Ratio	-11.64	13.06	275.68	27.75
Price / Sales	10.58	1,374.07	658.29	96.42
Price / Cash	N/A	122.60	77.60	38.88
Price / Book	5.82	16.63	10.93	4.64
Net Income	-$204.63M	-$22.71M	$3.51B	$1.08B
7 Day Performance	-10.86%	-2.99%	-2.00%	-1.06%
1 Month Performance	-23.91%	-10.60%	-6.15%	-5.49%
1 Year Performance	37.85%	19.44%	7.44%	5.13%

Nuvation Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUVB Nuvation Bio	2.7402 of 5 stars	$5.12 -7.9%	$13.22 +158.2%	+38.2%	$1.80B	$169.90M	N/A	305	News Coverage Analyst Forecast High Trading Volume
CYTK Cytokinetics	2.1988 of 5 stars	$66.16 +2.3%	$103.37 +56.2%	+16.5%	$8.05B	$88.04M	N/A	673
ABVX Abivax	2.5607 of 5 stars	$96.85 +6.4%	$156.69 +61.8%	+12.1%	$7.95B	N/A	N/A	69
PRAX Praxis Precision Medicines	2.0415 of 5 stars	$285.65 +1.7%	$612.42 +114.4%	+435.4%	$7.84B	$8.55M	N/A	110	News Coverage
SYRE Spyre Therapeutics	2.0655 of 5 stars	$85.79 +0.1%	$109.69 +27.9%	+483.2%	$7.54B	$890K	N/A	112	Trending News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NUVB) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvation Bio (NUVB) Competitors

NUVB vs. CYTK, ABVX, PRAX, SYRE, and IONS

How does Nuvation Bio compare to Cytokinetics?

Summary

How does Nuvation Bio compare to Abivax?

Summary

How does Nuvation Bio compare to Praxis Precision Medicines?

Summary

How does Nuvation Bio compare to Spyre Therapeutics?

Summary

How does Nuvation Bio compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvation Bio (NUVB) Competitors

NUVB vs. CYTK, ABVX, PRAX, SYRE, and IONS

How does Nuvation Bio compare to Cytokinetics?

Does the media favor NUVB or CYTK?

Is NUVB or CYTK more profitable?

Do analysts rate NUVB or CYTK?

Which has more risk and volatility, NUVB or CYTK?

Do insiders & institutionals hold more shares of NUVB or CYTK?

Which has stronger earnings and valuation, NUVB or CYTK?

Summary

How does Nuvation Bio compare to Abivax?

Do institutionals and insiders hold more shares of ABVX or NUVB?

Is ABVX or NUVB more profitable?

Do analysts prefer ABVX or NUVB?

Which has preferable valuation & earnings, ABVX or NUVB?

Which has more volatility and risk, ABVX or NUVB?

Does the media prefer ABVX or NUVB?

Summary

How does Nuvation Bio compare to Praxis Precision Medicines?

Do insiders and institutionals hold more shares of PRAX or NUVB?

Do analysts prefer PRAX or NUVB?

Does the media favor PRAX or NUVB?

Which has more volatility & risk, PRAX or NUVB?

Is PRAX or NUVB more profitable?

Which has stronger earnings and valuation, PRAX or NUVB?

Summary

How does Nuvation Bio compare to Spyre Therapeutics?

Which has more volatility & risk, NUVB or SYRE?

Is NUVB or SYRE more profitable?

Which has preferable earnings & valuation, NUVB or SYRE?

Does the media prefer NUVB or SYRE?

Do analysts recommend NUVB or SYRE?

Do insiders and institutionals hold more shares of NUVB or SYRE?

Summary

How does Nuvation Bio compare to Ionis Pharmaceuticals?

Which has more risk & volatility, NUVB or IONS?

Is NUVB or IONS more profitable?

Does the media prefer NUVB or IONS?

Which has stronger valuation & earnings, NUVB or IONS?

Do insiders and institutionals have more ownership in NUVB or IONS?

Do analysts prefer NUVB or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVB vs. The Competition

Nuvation Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools